U.K. earmarks extra $78M for cancer drugs; EU regulators accuse Servier of deceit;

 @FiercePharma: King Pharma reps lose fight for overtime pay. Report | Follow @FiercePharma

> Genzyme shows fight in manufacturing comeback. Article

> Britain is providing an extra £50 million ($78 million) to pay for cancer medicines from October, bringing forward a government promise to give access to drugs even if they have not been approved by cost watchdog NICE. Report

> Europe's top competition regulator has accused French pharmaceutical company Servier of providing "incorrect and misleading" information during a Brussels probe into the drugs sector. News

> While all epilepsy drugs carry a warning about an increased risk of suicidal behavior, it may only be certain newer medications that are connected to the hazard, a study published Monday suggests. Article

> Gilead Sciences will sell $2.2 billion in convertible notes, using almost half of the proceeds to buy back at least $1 billion in common stock from the purchasers of the notes. News

> Every two percent uptick in the substitution of generic drugs for brand-name products saves Medicaid $1 billion a year, according to a report released by the Generic Pharmaceutical Association (GPhA). Item

> Sharing the cost of expensive new cancer medicine with drugs companies is becoming increasingly common in the U.K., but the complexity of the reimbursement procedure means around half the total costs are not being recovered. Report

> Patients in the UK with myelodysplastic syndromes will be celebrating news that the National Institute for Health and Clinical Excellence has been ordered to reassess Celgene's Vidaza for the National Health Service. Report

> AmerisourceBergen (ABC.N) posted higher-than-expected quarterly profit growth, helped by strong sales of more profitable generic medicines and expense controls, and the drug wholesaler raised its fiscal-year forecast. Story

Biotech News

 @FierceBiotech: Is a bidding war for Genzyme looming? Report | Follow @FierceBiotech

> Cytori gains European OK for stem cell tech. Article

> Antares Pharma shares jump on upbeat PhIII results. Story

> AZ's Brilinta garners favorable reviews from FDA staffers. Report

Research News

> Nasal spray vax for meningitis may offer cheap alternative. Report

> "Longevity gene" used to cure Alzheimer's in mice. Article

> Researchers ID a key culprit in the aging process. News

> Study: Animal molecule in drugs triggers immune response. Item

Manufacturing News

> Bill to boost chemical safety may burden manufacturers. Report

> Cellexus joins disposables fray. Report

> DHL boosts cold chain strength in Nigeria. Story

> India seeks anti-fakes tools to preserve reputation. News

And Finally... Can Ritalin help people overcome drug addiction? Article

Suggested Articles

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.